Cart
sales@molnova.com
ISAM-140
CAS No. 932191-62-3
ISAM-140( —— )
Catalog No. M34288 CAS No. 932191-62-3
ISAM-140 is a potent and highly selective antagonist of A2B adenosine receptor.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 72 | In Stock |
|
| 5MG | 72 | In Stock |
|
| 10MG | 105 | In Stock |
|
| 25MG | 169 | In Stock |
|
| 50MG | 250 | In Stock |
|
| 100MG | 355 | In Stock |
|
| 200MG | 483 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameISAM-140
-
NoteResearch use only, not for human use.
-
Brief DescriptionISAM-140 is a potent and highly selective antagonist of A2B adenosine receptor.
-
DescriptionISAM-140 (22b) is a potent and highly selective A2B adenosine receptor antagonist with a Ki of 3.49 nM.
-
In VitroISAM-140 (22b) (0.1-100 μM) inhibits NECA (5'-N-ethylcarboxamido adenosine)-stimulated cAMP accumulation.ISAM-140 shows a KB value of 27.00 nM.
-
In Vivo——
-
Synonyms——
-
PathwayGPCR/G Protein
-
TargetAdenosine Receptor
-
RecptorAdenosine Receptor
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number932191-62-3
-
Formula Weight337.37
-
Molecular FormulaC19H19N3O3
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESC(OC(C)C)(=O)C=1C(N2C(NC=3C2=CC=CC3)=NC1C)C4=CC=CO4
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. El Maatougui A, et al. Discovery of Potent and Highly Selective A2B Adenosine Receptor Antagonist Chemotypes. J Med Chem. 2016 Mar 10;59(5):1967-83. ?
molnova catalog
related products
-
CGS 21680 hydrochlor...
CGS 21680 is a specific adenosine A2A subtype receptor agonist with Ki of 27 nM.
-
GW-493838
GW-493838 is a potent adenosine A1A receptor agonist for the treatment of dyslipidemia and neuropathic pain, with analgesic effects on post-herpetic neuralgia or peripheral nerve damage caused by trauma or surgery.
-
Ciforadenant
A potent, orally active, adenosine A2A receptor antagonist that is being investigated in solid tumors as a single agent and in combination with the anti-PD-L1 antibody atezolizumab.
